The Role of Microparticles as a Biomarker

The Role of Microparticles as a Biomarker in Distinguishing Between Thrombotic Thrombocytopenic Purpura (TTP) and Atypical Hemolytic Uremic Syndrome (aHUS)

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02626663

Enrollment

Registered

2015-12-10

Start date

2016-07-31

Completion date

2022-12-31

Last updated

2019-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atypical Hemolytic Uremic Syndrome, Microangiopathic Hemolytic Anemia, Microparticles, Thrombotic Thrombocytopenic Purpura

Brief summary

The investigators propose to characterize MPs in aHUS and TTP both at the onset and throughout treatment. The investigators believe that the number, size, and cell origin of MPs will differ between these two diseases. The hypothesis is that endothelial derived MPs will be higher in number and comprise a larger portion of the MP population in aHUS and that platelet MPs will comprise a larger number and greater proportion of MPs in TTP. The investigators believe that MP identity and number can be used to reliably differentiate between aHUS and TTP at disease onset.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 120 Years

Healthy volunteers

Inclusion criteria

* Patients with MAHA, TTP, and/or aHUS

Exclusion criteria

* Prisoners

Design outcomes

Primary

Measure	Time frame
Microparticle/Nanoparticle number (an absolute number)	an average of 3 months
Microparticle/Nanoparticle size (in nanometers or micrometers)	an average of 3 months
Microparticle/Nanoparticle identity (identity of cell type from which they are derived)	an average of 3 months

Secondary

Measure	Time frame
Morbidities	3 months
Mortality	3 months

Countries

United States

Outcome results